Valuation: Glenmark Pharmaceuticals Limited

Market Cap 631B 6.55B 5.73B 5.29B 4.87B 9.19B 9.39B 63.2B 24.83B 309B 24.61B 24.07B 1,064B P/E 2026
44.2x
P/E 2027 * 26.8x
Enterprise Value 592B 6.14B 5.37B 4.96B 4.57B 8.62B 8.8B 59.27B 23.28B 290B 23.08B 22.57B 998B EV / Sales 2026
3.51x
EV / Sales 2027 * 3.56x
Free-Float
51.03%
Yield 2026
0.12%
Yield 2027 * 0.24%
1 day-2.25%
1 week-1.40%
Current month+1.42%
1 month+3.65%
3 months-0.62%
6 months+11.74%
Current year+9.84%
1 week 2,229
Extreme 2229
2,326.1
1 month 2,135
Extreme 2135
2,326.1
Current year 1,842
Extreme 1842
2,474
1 year 1,792.6
Extreme 1792.6
2,474
3 years 702
Extreme 702
2,474
5 years 348.5
Extreme 348.5
2,474
10 years 161.65
Extreme 161.65
2,474
Manager TitleAgeSince
Chief Executive Officer 56 31/12/1999
Director of Finance/CFO 54 26/05/2025
President - 14/09/2023
Director TitleAgeSince
Director/Board Member 58 -
Chairman 56 11/05/2011
Director/Board Member 85 13/08/2009
Change 5-day change 1-year change 3-year change Capi.($)
-2.25%-1.40%+1.39%+218.40% 6.7B
-0.90%-0.31%+13.62%+80.12% 48.56B
-0.23%-0.63%+67.00%+115.81% 35.65B
-0.76%-1.57%-3.87%+37.62% 11.98B
-0.88%-1.32%+18.04%+92.11% 11.95B
0.00%+1.90%+34.67%+129.06% 9.29B
-0.75%-0.17%+18.85%+36.91% 6.95B
+3.37%-0.96%+46.11%-4.38% 6.79B
-9.93%+5.82%-22.89%+16.29% 6.81B
-0.97%+3.38%+22.66%+136.78% 4.48B
Average -1.33%+0.95%+19.56%+85.87% 14.91B
Weighted average by Cap. -0.94%+0.45%+26.41%+88.38%

Financials

2026 2027 *
Net sales 153B 1.59B 1.39B 1.28B 1.18B 2.23B 2.28B 15.34B 6.03B 74.97B 5.97B 5.84B 258B 167B 1.73B 1.51B 1.4B 1.29B 2.43B 2.48B 16.7B 6.56B 81.63B 6.5B 6.36B 281B
Net income 20.53B 213M 186M 172M 159M 299M 306M 2.06B 808M 10.05B 801M 783M 34.64B 23.28B 242M 211M 195M 180M 339M 346M 2.33B 916M 11.4B 908M 888M 39.28B
Net Debt -39.29B -408M -357M -329M -303M -572M -585M -3.94B -1.55B -19.24B -1.53B -1.5B -66.29B -37.12B -386M -337M -311M -287M -541M -552M -3.72B -1.46B -18.18B -1.45B -1.42B -62.63B
Logo Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited is an India-based, research-led, global pharmaceutical company. The Company hosts a diverse portfolio spanning branded, generics, and over-the-counter (OTC) segments. The Company is focused on the therapy areas of Respiratory, Dermatology and Oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. The Company’s offerings include complex injectables and biologics, oral solids, liquids, topical products, respiratory mdi1/dpi2/nasal sprays. It is focused on developing products for markets such as India, Russia & CIS, Brazil, Asia and Africa. Its brands include RYALTRIS and SALMEX / ASTHMEX. RYALTRIS, the Company's first global branded specialty drug for treating symptoms of seasonal allergic rhinitis. The Company's subsidiaries include Glenmark Pharmaceuticals Inc., Ichnos Sciences Inc., and Glenmark Holding SA.
Employees
15,800
Date Price Change Volume
17/07/26 ₹2,235.50 -2.25% 355,968
16/07/26 ₹2,286.90 -0.46% 158,181
15/07/26 ₹2,297.40 -0.33% 491,365
14/07/26 ₹2,305.10 +0.17% 706,821
13/07/26 ₹2,301.30 +0.81% 720,659
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,235.50INR
Average target price
2,497.27INR
Spread / Average Target
+11.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLENMARK Stock